Peter Harris

Peter Harris has over 10 years of experience in the biopharmaceutical industry. From 2009 to 2015, they worked for Genzyme as the VP Oncology & Renal Medicine and Global Team Leader Early Development. In 2012, they were appointed as Medical Consultant and Acting CMO for Autifony Therapeutics Ltd. In 2013, they were appointed as Chief Medical Officer for NeRRe Therapeutics Ltd. From 2015 to present, they have been working as Development Consultant and CMO for Artios Pharma Ltd, a recent Series A funded biotech company specialising in the DDR (DNA damage response) field and starting with assets presently within Cancer Research Technology portfolio.

Peter Harris attended Mill Hill School.